v
Search
Advanced

Publications > Journals > Latest Articles

Results per page:
v
Original Article Open Access
Gen Li, Ming Cheng, Jian He, Dengfeng Huang, Yingying Zhou, Yaohui Gao, Yuming Sun, Zhizhen Li
Published online November 17, 2026
Journal of Clinical and Translational Hepatology. doi:10.14218/JCTH.2026.00174
Abstract
Intraoperative hypotension (IOH) is a common and serious complication associated with increased perioperative morbidity and mortality. Although obstructive jaundice is often accompanied [...] Read more.

Intraoperative hypotension (IOH) is a common and serious complication associated with increased perioperative morbidity and mortality. Although obstructive jaundice is often accompanied by hemodynamic instability, its mechanistic contribution to IOH remains unclear. In this study, we aimed to determine whether jaundice affects IOH and elucidate the underlying mechanism.

Clinical data from 139 patients who underwent pancreatoduodenectomy were retrospectively analyzed for predictors of IOH. Vascular tissues from jaundiced and non-jaundiced patients were subjected to single-cell RNA sequencing for cell-specific molecular exploration. Key findings were validated by immunohistochemistry in a stratified random sample from the study cohort. In a rat bile duct ligation model, aortic endothelin-1 (EDN1) expression and vascular function were assessed by Western blotting and ex vivo vascular reactivity assays. The mechanism was investigated in primary mouse aortic endothelial cells under TNF-α stimulation with or without NF-κB pathway inhibition.

Multivariable logistic regression identified jaundice as an independent predictor of IOH (odds ratio, 2.328; 95% confidence interval, 1.027–5.276; P = 0.043). Jaundiced tissues exhibited vascular cell remodeling, characterized by increased proportions of endothelial cells and macrophages and decreased proportions of fibroblasts and smooth muscle cells. EDN1 expression was significantly downregulated in jaundiced patients, and total bilirubin levels were negatively correlated with EDN1 protein expression (P < 0.001). Single-cell RNA sequencing of immune cells suggested suppression of the NF-κB pathway in jaundiced patients. In the bile duct ligation model, EDN1 expression in aortic tissue showed a time-dependent decrease. In TNF-α-stimulated primary mouse aortic endothelial cells, bilirubin or NF-κB inhibition with BAY 11-7082 suppressed EDN1 expression.

Biliary obstruction causing jaundice may contribute to IOH through suppression of NF-κB signaling and reduced endothelial EDN1 expression. These findings support further investigation of the NF-κB/EDN1 signaling axis as a potential therapeutic target for jaundice-associated IOH.

Full article
Letter to the Editor Open Access
Jiale Tang, Lingyu Ren, Chao Sun, You Deng
Published online November 17, 2026
Journal of Clinical and Translational Hepatology. doi:10.14218/JCTH.2026.00704
Original Article Open Access
Lucy Ogoke, Sangwook Michael Woo, Nicole Herbers, Michael Chen, Hua Yang, Amy Bazzarelli, Wei Xiong
Published online November 17, 2026
Journal of Clinical and Translational Pathology. doi:10.14218/JCTP.2026.00043
Abstract
Fine-wire-guided localization (FWGL) has traditionally been used for nonpalpable breast lesions although it can complicate specimen handling. Magnetic Occult Lesion Localization [...] Read more.

Fine-wire-guided localization (FWGL) has traditionally been used for nonpalpable breast lesions although it can complicate specimen handling. Magnetic Occult Lesion Localization and Imaging (MOLLI) is a wire-free alternative for which comparative pathologic data remain limited. This exploratory study examined margin status, morphometry, and specimen integrity.

We retrospectively analyzed 109 consecutive lumpectomy specimens (83 MOLLI, 26 FWGL) at a single academic center between March 2022 and April 2023, comprising 108 primary excisions and one re-excision. The localization method was not randomly assigned and appears to have depended on surgeon preference. Secondary invasive-carcinoma analyses used Firth penalized logistic regression to adjust for potential confounding.

After exclusion of 33 benign lesions, 76 carcinomas remained (62 invasive carcinomas and 14 cases of pure ductal carcinoma in situ), 75 with evaluable primary-excision margins. For the primary outcome, positive margins occurred in 13.8% (8/58) of MOLLI versus 17.6% (3/17) of FWGL cases (P = 0.70). In the secondary invasive-carcinoma analysis, positive margins occurred in 10.9% (5/46) versus 18.8% (3/16) (P = 0.41). Median specimen weight and volume did not differ significantly; specimen integrity was preserved in 98.8% (82/83) of MOLLI and 100% (26/26) of FWGL specimens.

In this exploratory study, MOLLI shows no detectable differences in margin status, morphometry, or specimen integrity relative to fine-wire localization. Unlike published data on a related magnetic-seed device, we observe no reduction in resected tissue volume, indicating that findings for one device should not be assumed to apply to another. The study is underpowered to detect small differences. These preliminary findings therefore require confirmation in larger studies.

Full article
Review Article Open Access
Kao-Cheng Huang, Ya-Ning Chang
Published online November 17, 2026
Future Integrative Medicine. doi:10.14218/FIM.2026.00026
Abstract
Midnight-noon ebb-flow (ziwu liuzhu) and circadian science are both temporalized models of the body, treating time of day as an intrinsic variable of physiology and therapeutic [...] Read more.

Midnight-noon ebb-flow (ziwu liuzhu) and circadian science are both temporalized models of the body, treating time of day as an intrinsic variable of physiology and therapeutic response, yet they differ fundamentally in theoretical units, causal claims, and standards of evidence. Ziwu liuzhu, a time-function model of traditional Chinese medicine, maps the 12 double-hours (shichen) onto the ebb and flow of qi and blood in the 12 channels (meridians); circadian science, an experimentally grounded mechanistic model, describes circadian rhythms generated by an endogenous, light-entrained timing system of the suprachiasmatic nucleus, clock genes, and peripheral clocks. Existing accounts tend either to conflate the two frameworks or to dismiss one in terms of the other. This narrative review compares the two frameworks’ conceptual structure, historical formation, mechanisms, evidence, and applications. Their genuine convergence lies in treating time as a variable in health and disease, not in any proven mechanism. Chronotherapy findings likewise do not validate the channel-hour correspondences. Fixed double-hour assignments do not correspond to the phase-adjustable, individually variable circadian system; the morphological basis of the channels remains unconfirmed; and the certainty of evidence for a timing-specific effect of ziwu liuzhu acupuncture appears low to very low. We distinguish three critical issues that are often conflated: the efficacy of timed acupuncture, its mechanism, and the anatomical status of the channels; evidence on the first two does not settle the third. We propose a layered research agenda that preserves the tradition’s historical and clinical value while rigorously evaluating its testable claims, chiefly through trials comparing identical needling given on-time and off-time, scheduled both by classical clock time and relative to measured circadian phase. We conclude that ziwu liuzhu is best treated as a source of testable hypotheses, and that no clinical efficacy should be claimed for its timing principle until it has been demonstrated.

Full article
Review Article Open Access
Tian Li, Yong Yuan, Xiaofeng Li, Xiaoxia Hao
Published online November 17, 2026
Journal of Clinical and Translational Hepatology. doi:10.14218/JCTH.2026.00343
Abstract
Liver fibrosis is a dynamic and partially reversible pathological process driven by chronic liver injury, yet effective antifibrotic therapies remain limited. Astragaloside IV (AS-IV), [...] Read more.

Liver fibrosis is a dynamic and partially reversible pathological process driven by chronic liver injury, yet effective antifibrotic therapies remain limited. Astragaloside IV (AS-IV), a major bioactive constituent isolated from Astragalus mongholicus Bunge, exerts a broad range of pharmacological effects, including anti-inflammatory, antioxidant, and antifibrotic effects. This review synthesizes current evidence on the pharmacological characteristics, mechanistic basis, preclinical efficacy, and translational challenges of AS-IV in liver fibrosis. Available evidence indicates that AS-IV exerts its antifibrotic effects primarily by suppressing hepatic stellate cell activation, with modulation of transforming growth factor-β/Smad signaling representing the most consistently supported mechanism. Beyond this principal pathway, AS-IV may attenuate profibrotic amplification loops by enhancing antioxidant responses and suppressing inflammatory signaling, while also reducing upstream profibrotic stimuli through hepatoprotective effects. However, its clinical translation remains limited by poor oral bioavailability, inadequately defined pharmacokinetic-pharmacodynamic relationships, and a lack of high-quality clinical evidence. Overall, AS-IV represents a promising preclinical antifibrotic candidate, although clinical efficacy and pharmacological optimization remain to be established.

Full article
Original Article Open Access
Fangqian Du, Xiangyan Zhang, Yuwei Xie, Hao Zou, Kun Li, Kui Liu, Praveena George, Bingzi Dong, Chengzhan Zhu
Published online November 17, 2026
Journal of Clinical and Translational Hepatology. doi:10.14218/JCTH.2026.00370
Abstract
Extrahepatic cholangiocarcinoma (eCCA) is often accompanied by biliary obstruction and alterations in bile composition, which may affect the tumor microenvironment. KPNB1 is a key [...] Read more.

Extrahepatic cholangiocarcinoma (eCCA) is often accompanied by biliary obstruction and alterations in bile composition, which may affect the tumor microenvironment. KPNB1 is a key nuclear transport receptor that is aberrantly expressed in various malignancies. However, KPNB1’s role in cholangiocarcinoma (CCA) remains unclear. In this study, we aimed to investigate the biological role and underlying molecular mechanisms of KPNB1 in CCA progression and explore its association with the biliary microenvironment.

To investigate the role of KPNB1 in CCA, we analyzed its expression and clinical significance using public databases and clinical specimens and performed a series of in vitro and in vivo functional experiments. The antitumor effects of the KPNB1 inhibitor importazole were assessed in vitro and in vivo. The KPNB1-LDHA-SOX2 signaling pathway was investigated using mass spectrometry, immunoprecipitation, and rescue assays. Furthermore, KPNB1 levels in bile were analyzed, and their clinical value was evaluated.

KPNB1 was markedly overexpressed in eCCA tissues and was associated with aggressive clinicopathological features and poor prognosis. Functional analyses demonstrated that KPNB1 enhanced CCA cell proliferation, migration, invasion, epithelial–mesenchymal transition, and stemness-related characteristics of CCA cells, whereas importazole significantly inhibited these malignant phenotypes and tumor growth. Mechanistically, KPNB1 enhanced the expression of stemness-related genes by promoting the nuclear accumulation of LDHA and its interaction with SOX2. Furthermore, eCCA-derived bile enhanced malignant phenotypes and KPNB1 protein expression in CCA cells, while eCCA bile-derived exosomes were enriched in KPNB1 and exerted similar tumor-promoting effects.

KPNB1 promotes cholangiocarcinoma progression through the KPNB1-LDHA-SOX2 axis and may contribute to tumor progression within the biliary microenvironment. Elevated KPNB1 levels in bile may have potential prognostic value, and targeting KPNB1 may represent a promising therapeutic strategy for cholangiocarcinoma.

Full article
Review Article Open Access
He Ma, Jia-Rui Zheng, Xin-Kun Liu, Lin-Xiang Huang, Yan-Di Xie, Bo Feng
Published online November 17, 2026
Journal of Clinical and Translational Hepatology. doi:10.14218/JCTH.2026.00549
Abstract
Achieving a functional cure for chronic hepatitis B remains challenging, primarily due to the inability to reconstitute effective host immune responses against the virus. The unexpected [...] Read more.

Achieving a functional cure for chronic hepatitis B remains challenging, primarily due to the inability to reconstitute effective host immune responses against the virus. The unexpected functional cure of chronic hepatitis B following allogeneic hematopoietic stem cell transplantation provides a unique proof-of-principle model for immune-mediated HBsAg clearance. This review aims to elucidate that the core mechanism underlying hematopoietic stem cell transplantation-mediated HBsAg clearance lies in “adoptive immune transfer”, and to explore design principles and future directions for modern cell-based immunotherapies based on this mechanism. We reviewed available case reports and meta-analytic evidence, acknowledging their limitations, and dissected the immunological mechanisms by which donor-derived hepatitis B virus-specific T and B cells may jointly reconstitute adaptive immunity and break host immune tolerance. We then comparatively evaluated the technical characteristics and limitations of chimeric antigen receptor T cell therapy and T-cell receptor-engineered T-cell therapy. Current engineered T-cell therapies, while translating the core principle of adoptive transfer, exhibit fundamental limitations including monoclonal specificity, inability to remodel the host microenvironment, and absence of durable humoral reconstitution. A broader functional-cure strategy may require adopting the paradigm of synergy and systemic immune reshaping exemplified by hematopoietic stem cell transplantation. Future strategies should develop temporally optimized, multilayered combination therapies, offering a possible pathway for next-generation therapeutics capable of systemically rebuilding antiviral immunity.

Full article
Original Article Open Access
Khalid M. AlNaamani, Sultan AlBalushi, Mohamed El-Kassas, Hilal Alsabti, Siham AlSinani, Saleh A. Alqahtani, Khalid A. Alswat, Tarannum Behlim, Waleed K. Al-Hamoudi, Faisal M. Sanai, Faisal Abaalkhail, Saad A. AlGhamdi, Zobair M. Younossi
Published online November 17, 2026
Journal of Clinical and Translational Hepatology. doi:10.14218/JCTH.2026.00740
Abstract
Across the Middle East and North Africa (MENA), the age-standardized rates (ASRs) of hepatitis B virus (HBV) burden may be declining while the absolute burden rises among middle-aged [...] Read more.

Across the Middle East and North Africa (MENA), the age-standardized rates (ASRs) of hepatitis B virus (HBV) burden may be declining while the absolute burden rises among middle-aged and older adults. In this study, we aimed to characterize changes in rates, counts, and age distribution across 21 MENA countries, with Oman as a case study.

We analyzed Global Burden of Disease 2023 estimates for 1990–2023. Disability-adjusted life-years (DALYs) were used to measure the overall HBV-related burden, and acute hepatitis B incidence was examined as a secondary outcome. We compared population-weighted means of country ASRs with aggregated counts, assessed rate-count divergence, and summarized DALYs across four fixed age bands.

The population-weighted mean DALY ASR declined 53.0%, from 624.5 to 293.6 per 100,000 (estimated annual percentage change −2.28%; 95% confidence interval −2.34 to −2.23), while absolute DALYs increased 19.3%, from 1.18 to 1.41 million. Mean burden age increased in 20 countries, by up to 12.4 years, and the 0–34-year DALY share declined in 19 countries. In Oman, DALYs and acute-incidence ASRs declined 38.6% and 49.2%, while DALYs at ages 35–54 increased 2.55-fold and represented 43.3% of national HBV DALYs in 2023.

HBV burden in MENA is shifting toward middle-aged and older adults while absolute DALYs rise despite declining ASRs. Service planning should consider counts and age distribution alongside rates, with sustained vaccination complemented by adult diagnosis, treatment, cirrhosis care, and hepatocellular carcinoma surveillance.

Full article
Letter to the Editor Open Access
Wen-Wen Luo, Da-Long Yang, Jian-Hong Zhong, Yi-Li Ma, Zhen-Zhen Li
Published online November 16, 2026
Journal of Clinical and Translational Hepatology. doi:10.14218/JCTH.2026.00709
Review Article Open Access
Di Meng, Zhenyao Jiang, Yingcheng Yao, Mingming Ye, Sitian Zhao, Mingyang Jin, Jie Li, Junping Shi
Published online November 16, 2026
Journal of Clinical and Translational Hepatology. doi:10.14218/JCTH.2026.00242
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a chronic liver disease associated with obesity, insulin resistance, and metabolic syndrome and has become a [...] Read more.

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a chronic liver disease associated with obesity, insulin resistance, and metabolic syndrome and has become a major global health challenge. Current management relies primarily on comprehensive lifestyle interventions, including dietary modification, regular physical activity, weight loss, management of metabolic risk factors, and emerging pharmacotherapies. The gluten-free diet (GFD) was originally developed for the treatment of celiac disease and has attracted attention in recent years for its potential metabolic benefits. Existing studies suggest that gluten- or wheat-targeted dietary interventions may affect MASLD-related pathways, including the gut microbiota, inflammation, insulin sensitivity, and liver fat accumulation. In patients with concurrent celiac disease and MASLD, a GFD is indicated for celiac disease, but its hepatic and metabolic effects are variable. However, clinical and mechanistic evidence for its potential effects in patients with non-celiac MASLD is limited and heterogeneous, relying largely on indirect evidence from animal models; furthermore, long-term, unsupervised adherence to a GFD may adversely affect metabolic health. This narrative review critically evaluates the therapeutic boundaries of gluten-targeted interventions, compares the gluten-free diet with established dietary patterns, and outlines challenges related to nutritional adequacy, cost, and adherence. Future research should focus on high-quality randomized controlled trials to identify the specific benefits and risks of gluten removal in patients with non-celiac MASLD and to inform more precise dietary guidance.

Full article
PrevPage 1 of 10 12345…910Next
Back to Top